Parsortix Liquid Biopsy

Preliminary Results for the year ended
30 April 2017

Andrew Newland and Ian Griffiths
27 July 2017
This presentation has been prepared by ANGLE plc (the "Company"). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions.

The information and opinions contained in this presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this presentation and any errors therein or omissions therefrom.

This presentation does not constitute or form any part of, and should not be construed as, an offer to sell, or an invitation or solicitation or recommendation to purchase, or subscribe for or underwrite or otherwise acquire any securities in the Company in any jurisdiction and does not constitute or form part of a prospectus. No part of this presentation should form the basis of, or be relied on in connection with, or act as any inducement to enter into, any contract or commitment or investment decision whatsoever. The Company's nominated adviser, Cenkos Securities PLC ("Cenkos") has not approved this document for the purposes of section 21 of the Financial Services and Markets Act 2000 (“FSMA”) and accordingly it is a communication made only to persons who (a) fall within one or more of the exemptions from section 21 of FSMA contained in articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (which includes persons who are authorised or exempt persons within the meaning of FSMA, certain other investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts) and persons who are otherwise permitted by law to receive it and (b) are an "eligible counterparty" within the meaning of Article 24(2), (3) and (4) of Directive 2004/39/EC ("MiFID") as implemented into national law of the relevant EEA state. Any investment or investment activity to which this document relates is only available to such persons. Persons of any other description, including those who do not have professional experience in matters relating to investments, should not rely on this document or act on its contents for any purpose whatsoever and should return it to Cenkos immediately.

This presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under the Financial Services and Markets Act 2000).

This presentation contains certain statements that are neither reported financial results nor other historical information. These statements include information with respect to the Company's financial condition, its results of operations and businesses, strategy, plans and objectives. Words such as "anticipates", "expects", "should", "intends", "plans", "believes", "outlook", "seeks", "estimates", "targets", "may", "will", "continue", "project" and similar expressions, as well as statements in the future tense, identify forward-looking statements. These forward-looking statements are not guarantees of the Company's future performance and are subject to assumptions, risks and uncertainties that could cause actual future results to differ materially from those expressed in or implied by such forward-looking statements. Many of these assumptions, risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely and include, but are not limited to, the general economic climate and market conditions, as well as specific factors including the success of the Group’s research and development and commercialisation strategies, the uncertainties related to regulatory clearance and the acceptance of the Group’s products by customers.

For further details regarding these and other assumptions, risks and uncertainties that may affect the Group, please read the Directors’ Report section including the “Principal risks and uncertainties” in the most recent Annual Report & Accounts of ANGLE plc. In addition, new factors emerge from time to time and the Company cannot assess the potential impact of any such factor on its activities or the extent to which any factor, or combination of factors, may cause actual future results to differ materially from those contained in any forward-looking statement. Except as may be required by law or regulation, the Company undertakes no obligation to update any of its forward-looking statements, which speak only as of the date of this document.
Highlights

Liquid Biopsy

ANGLE’s Parsortix system

- Simple blood test for personalised cancer care
- Proven performance with multiple Key Opinion Leaders
- Emerging $ multi-billion market (Goldman Sachs $14bn in US alone by 2025)
- Circulating tumor cell (CTC) solution with strong competitive differentiation
- Product based solution with instruments and cassettes

- Positive results from 400 patient Ovarian Cancer studies in Europe and US
- MD Anderson leading 400 patient Breast Cancer FDA clinical study. Analytical study in progress.
- Barts Prostate Cancer detection and grading – CTCs and megakaryocytes positive studies
- Research use by world-leading cancer centres building with growing body of published evidence
## Financial Results for the year ended 30 April 2017 (unaudited)

### Statement of Comprehensive Income

<table>
<thead>
<tr>
<th></th>
<th>2017 £'000</th>
<th>2016 £'000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>498</td>
<td>361</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>(123)</td>
<td>(107)</td>
</tr>
<tr>
<td>Gross profit</td>
<td>376</td>
<td>254</td>
</tr>
<tr>
<td>Operating costs</td>
<td>(7,810)</td>
<td>(5,703)</td>
</tr>
<tr>
<td>Tax credit and other income</td>
<td>1,043</td>
<td>331</td>
</tr>
<tr>
<td><strong>Loss for the year</strong></td>
<td>(6,392)</td>
<td>(5,118)</td>
</tr>
</tbody>
</table>

### Statement of Financial Position

<table>
<thead>
<tr>
<th></th>
<th>30Apr17</th>
<th>30Apr16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade and other receivables and tax</td>
<td>1,975</td>
<td>798</td>
</tr>
<tr>
<td>Inventories</td>
<td>665</td>
<td>376</td>
</tr>
<tr>
<td>Cash</td>
<td>5,536</td>
<td>3,764</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>824</td>
<td>455</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>1,918</td>
<td>1,346</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>10,918</td>
<td>6,739</td>
</tr>
</tbody>
</table>

### Comments
- Research use sales established and growing
- 75% gross margin
- Planned expenditure on clinical studies
- Cash position strengthened
Parsortix™ – the Complete Picture

- Intact CTCs not just ctDNA
  Compatible with existing downstream analysis techniques

- Parsortix captures living cancer cells
  These cannot be present unless the patient has cancer

- Evidence-based driven by KOLs and clinical studies

- Patented product solution

- Scaleable business with third party manufacture
**Benefits of Parsortix CTCs**

<table>
<thead>
<tr>
<th>Source</th>
<th>Solid tissue biopsy</th>
<th>Liquid biopsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample type</td>
<td>Primary tumour</td>
<td>CTCs¹</td>
</tr>
<tr>
<td></td>
<td>Intact cells</td>
<td>Intact cells</td>
</tr>
<tr>
<td>Procedure</td>
<td>Catalytic</td>
<td>Fragmented DNA</td>
</tr>
<tr>
<td>Sample accessibility</td>
<td>Invasive</td>
<td>Non-invasive³</td>
</tr>
<tr>
<td>Patient recovery time</td>
<td>Not always accessible</td>
<td>Accessible</td>
</tr>
<tr>
<td>Test costs</td>
<td>Varies</td>
<td>None</td>
</tr>
<tr>
<td>Test turnaround time</td>
<td>Varies</td>
<td>Lower</td>
</tr>
<tr>
<td>Repeatability</td>
<td>Varies – difficult</td>
<td>Shorter</td>
</tr>
<tr>
<td>Molecular analysis</td>
<td>DNA</td>
<td>Easy</td>
</tr>
<tr>
<td></td>
<td>RNA</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Protein</td>
<td>Yes</td>
</tr>
<tr>
<td>Live cells</td>
<td>Cell culture</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Xenograft</td>
<td>Yes</td>
</tr>
<tr>
<td>Standard of care</td>
<td>Proven</td>
<td>Not yet proven</td>
</tr>
</tbody>
</table>

1. CTCs are live cancer cells circulating in the blood known as circulating tumour cells
2. cfDNA also known as ctDNA is cell-free circulating fragments of DNA from dead cells, which may be found in the plasma component of the blood
3. Tissue obtained from simple peripheral blood test
4. Access to CTCs technically challenging given low number of CTCs present and historically has been very difficult. ANGLE's Parsortix system has been specially designed to address this issue
Far-reaching market potential

Evidence-based approach to prove performance with ovarian cancer, FDA breast cancer
Substantiating value as sample collection platform
Partnering strategy for widespread deployment

Emerging $ multi-billion market (Goldman Sachs $14bn in US alone by 2025)

- **Detection of ovarian cancer key unmet medical need**

- **US market statistics**
  - 750,000 women p.a. abnormal pelvic mass
  - >200,000 women have surgery
  - 10-11% have cancer

- **Women with cancer need expensive, specialist cancer surgeon**
  - in the US, women typically have a specialist surgeon leading to wasted resources in 90% of cases
  - in Europe, women typically have a general surgeon leading to poor outcomes for the 10% with cancer

- **Existing tests CA125, OVA-1 and ROMA suffer from low sensitivity and/or low specificity**

- **Medical University of Vienna pilot study showed Parsortix with high sensitivity and high specificity**

> **Professor Robert Zeillinger, Head of the Molecular Oncology Group at the Department of Obstetrics and Gynaecology, Medical University of Vienna** “The 200 patient ANG-001 clinical multi-centre study has shown that the Parsortix based test allows us to successfully discriminate patients with ovarian cancer from patients with a non-malignant pelvic mass with a high degree of accuracy.”
Clinical application

Ovarian cancer clinical studies: 400 patients

- 400 patient European (ANG-001) and United States (ANG-003) studies
  - Medical University of Vienna, Charité and Vivantes
  - University of Rochester Wilmot Cancer Center

- Both studies report positive results

- Potential to significantly out-perform current clinical care in discriminating malignant from benign
  - up to 95% sensitivity and nearly double specificity of CA125
  - provide valuable gene expression information on malignant cases

Moving to Optimisation and Validation Phase

- Optimisation (6 months) to improve performance still further

- Validation studies (12-18 months) to support CE Mark and FDA clearance

- Opportunities for accelerated commercialisation via commercial partnerships

- £300 million per annum market

Dr Richard Moore, Director of the Gynecologic Oncology Division, University of Rochester Medical Center Wilmot Cancer Institute

"The 200 patient ANG-003 clinical study shows that the Parsortix test has the ability to accurately discriminate malignant from benign pelvic masses prior to biopsy or surgery. The test also offers key additional benefits over existing practice through the gene expression information it provides, which may help to further guide choices for targeted therapy in women with ovarian cancer. Additionally, the test may allow separate identification of patients with low malignant potential and/or other cancer types using a non-invasive liquid biopsy test."
Breast cancer FDA clearance progress (400 patient study)

- **Potential to be first FDA cleared system for harvesting cancer cells from blood**
- Seeking FDA clearance in metastatic breast cancer
  - breadth of clearance to provide flexibility
  - base clearance to which specific clinical uses can be added
  - ovarian cancer and other cancer types to follow
- **Analytical studies in progress**
  - precision and reproducibility (internally and externally)
  - limits of quantification and detection
  - accuracy and linearity
  - potential interferents and carryover
- **FDA clearance will differentiate Parsortix in markets worldwide**

- **ANG-002 clinical study plan developed in consultation with several world-class US breast cancer centres**
  - designed to meet FDA regulatory requirements
  - 200 metastatic breast cancer patients and 200 age appropriate healthy volunteers
- **MD Anderson, #1 cancer centre in the US, contracted to lead ANGLE FDA clinical study**
- Contractual negotiations with 6 major cancer centres in progress
- **Results expected H1 2018**
Breast cancer metastatic biopsy comparison

University of Southern California Norris Comprehensive Cancer Center

- CTCs harvested and RNA-Seq analysis successful for 100% of patients

- **CTCs from Parsortix liquid biopsy had similar patterns of expression for 192 genes to the traditional biopsy of cancer cells from metastatic sites in all cases (21 patient study)**

- Wide range of metastatic sites
  
  Skin, pleural effusion (fluid around the lung), pericardial effusion (fluid around the heart), breast, cerebrospinal fluid (fluid found in brain and spine) and bone tissue

- **CTCs provide information on 66 different pathways that may be targeted by new or existing cancer drugs**

- Parsortix provides clinical information beyond a single metastatic site

- Metastatic biopsies invasive, often requiring surgery, expensive and may delay treatment. Often they are not possible at all
Non-invasive metastatic breast cancer biopsy: £1 billion p.a. market potential

Non-invasive, repeatable, lower cost, more effective

ANGLE FDA study in metastatic breast cancer to investigate RNA-Seq (full next generation sequencing) in larger patient sample

Multiple commercial opportunities
- repeat biopsy allowing targeted treatment
- tool for identifying drug targets in metastatic breast cancer
- tool to assess the effectiveness of drugs under development in clinical trials

Most common cancer in women - 1.7 million cases recorded in 2012 and 6.3 million women living with breast cancer. 20% to 30% will become metastatic

Julie E. Lang, MD, FACS, Director, USC Breast Cancer Program, Associate Professor of Surgery, Norris Comprehensive Cancer Center, University of Southern California

“As a breast cancer surgeon, I am very enthusiastic about the potential of liquid biopsy ... Our pilot data shows that potentially the same information can be obtained from a simple blood test using Parsortix as from an invasive tissue biopsy and indeed may be advantageous over invasive tissue biopsies in regards to the diverse sites of metastatic disease ...”
Clinical application under consideration

**Non-invasive prostate biopsy using Parsortix £3 billion p.a. market potential**

- **Barts Cancer Institute pilot studies**
  - harvested CTCs in 100% of patients (52 patient study)
  - detected cancer in 100% of the metastatic prostate cancer patients and 75% early stage (80 patient study)
  - number of mesenchymal CTCs showed good correlation to Gleason score
  - metastatic or localised: CTCs showed higher level of accuracy than Gleason score

- **Simple blood test before solid biopsy test**
  - detect presence of prostate cancer
  - assess aggressiveness of disease
  - patient risk stratification – differentiate between active surveillance (indolent) or intervention (aggressive)

- **Avoid surgical intervention**
  - >1 million solid prostate biopsies p.a. in US
  - 75-80% no cancer and >50% with cancer “watchful waiting” / “active surveillance”. Only 10% needing treatment

---

**Dr Yong-Jie Lu, Reader in Medical Oncology at Barts Cancer Institute**

“The exciting part of this research is the potential for the Parsortix system to be used to assess the severity of the disease as well as to detect it. This meets a key medical need to avoid over-treatment as well as to ensure treatment is available for patients who need it.”
Prostate cancer metastasis and prediction of survival

Barts Cancer Institute

- Prostate cancer most common male cancer. 1.1 million new cases in 2012
- Number of Parsortix EMTing CTCs correlated with metastasis 92% accuracy (81 patient study)
- Out-performs current approaches – PSA level and Imaging
- Blood cell discovery with Parsortix: cells identified as megakaryocytes linked to patient survival (n=40)
- New Parsortix CMS (combined EMTed CTC and megakaryocyte score) predicts overall survival: patients 10x more likely to die
- Enables intensive treatment early

Kaplan Meier curve
Research use sales

- **Research use sales growing**
  - over 145 Parsortix instruments in active use and growing rapidly
  - over 30,000 blood separations have already been performed on the Parsortix system

- **Research use sales £250m p.a. market potential**
  - 750 addressable Phase II cancer drug trials p.a. revenue potential £100k / trial
  - 120 addressable Phase III cancer drug trials p.a. revenue potential £750k / trial

- **Targeting sales to leading cancer centres**
  - 50% of top 10 breast cancer researchers worldwide have now adopted Parsortix
  - over 50% of US NCCN Centres purchased or considering Parsortix
  - cancer centres independently researching 14 different cancer types using Parsortix

- **Growth potential: drug trials, CROs, mouse**

<table>
<thead>
<tr>
<th>Instrument Cassette</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price(^1) £40,000 £100</td>
</tr>
<tr>
<td>Cost(^1) £12,000 (^2) £17</td>
</tr>
<tr>
<td>Margin 70% 83%</td>
</tr>
</tbody>
</table>

1. Indicative. High margins allow flexibility in pricing for competitive advantage
2. Includes maintenance, technical support, sales and distribution
**Parsortix patented system developing a world-leading position in emerging $ multi-billion liquid biopsy market**

- Providing the **Complete Picture** (viable, intact CTCs for DNA, RNA, and protein analysis not just ctDNA)
- FDA study to support platform clearance for metastatic breast cancer with results expected H1 2018
- Ovarian cancer application successfully moved into optimisation / validation phase
- Prostate cancer application moving into verification phase
- Widespread adoption of Parsortix by leading cancer centres in Europe and the United States
  - numerous other cancer applications at KOL pilot study phase